TLIS Talis Biomedical Corp Insider Trading

10% owner Leonard Braden Michael buys 30,100 shares (2 transactions) at $1.47 avg while stock falls -81.1% in 90 days and -54.8% in 30 days

Leonard Braden Michael, a 10% owner of Talis Biomedical, executed 2 purchases totaling 30,100 shares for $44,240.00 on 2024-09-05 and 2024-09-06, increasing his holdings by 13.8%. The purchases occur amid severe recent price deterioration: the stock is down -81.1% over the prior 90 days and -54.8% over the prior 30 days, trading -81.7% below its 52-week high of $9.30. Concurrent with these buys, the company's fundamentals show deterioration, with annual revenue growth of -55.6% and a net loss of $-8,849,000.00 in the latest period. The insider's cross-ticker track record shows an average 30-day return of -4.7% on 20 prior buys across all tickers, providing limited reassurance about his buy-timing accuracy in volatile environments.

10% Owner Leonard Braden Michael buys 500 TLIS shares at $4.00 (Sep 2024); stock now $1.46, -84.3% from 52-week high.

Leonard Braden Michael, a 10% owner of Talis Biomedical, purchased 500 shares at $4.00 on 2024-09-03, increasing holdings to 218,602 shares. The purchase occurred when TLIS was trading significantly above current levels; the stock has since declined 84.3% from its 52-week high of $9.30 to the current price of $1.46. This represents one of four consecutive buys by this insider between 2024-08-26 and 2024-09-05, executed as the stock entered a steep decline. The company's fundamentals deteriorated sharply, with annual revenue growth of -55.6%, zero quarterly revenue, and a net loss of $-8,849,000 over the most recent full fiscal year. The timing of these purchases relative to the subsequent price collapse warrants attention to whether the insider possessed material information at the time of purchase.

10% Owner Braden Michael buys 151 TLIS shares at $4.25; stock now $1.37, -85.3% from 52-week high.

Leonard Braden Michael, a 10% owner, purchased 151 shares at $4.25 on 2024-08-30, a modest addition to his 218.5K-share position. The stock has since collapsed to $1.37, trading -85.3% below its 52-week high of $9.30 and down -84.6% over the past 30 days. The company is deeply distressed: revenue was $0.00 in the latest quarter, net income is negative at $-8.8M, and annual revenue has contracted -55.6% year-over-year. This transaction came just days before two additional purchases at the same ticker on 2024-08-28 and 2024-09-03, but all three TLIS trades remain unmeasurable at the 90-day horizon. Across his broader trading history, Braden Michael's 20 prior open-market purchases averaged a -3.1% return at 30 days, and none of his prior trades were well-timed at the 90-day mark, suggesting a pattern of inaccurate market timing.

10% owner Leonard Braden Michael buys 14,382 shares across 2 transactions for $56,137.01 as TLIS stock falls 55.9% from 52-week high.

Leonard Braden Michael, a 10% owner of Talis Biomedical, made 2 separate purchases totaling 14,382 shares for $56,137.01 on 2024-08-26 and 2024-08-28, increasing his holdings by 7.1% from 203,569 to 217,951 shares. The purchase occurred at a blended average price of $3.90, while the stock currently trades at $4.10, down 55.9% from its 52-week high of $9.30 and down 51.6% over the prior 30 days. The company is deeply unprofitable with a net income of $-8,849,000.00 and zero revenue in the latest quarter, with annual revenue declining 55.6% year-over-year. While Michael's cross-ticker track record shows 20 prior buys with an average 30-day return of +5.3%, this context does not account for the fundamental weakness in the underlying business or the severity of the stock's recent drawdown from prior highs.